Partnership between Sonrai and AOA Dx expedites ovarian cancer diagnostic test development
Sonrai Analytics and AOA Dx have announced a strategic partnership to accelerate the development of AOA's multi-omic liquid biopsy test for ovarian cancer. This collaboration aims to leverage AI-driven tools and multi-omic analyses to improve early detection and personalized treatment of ovarian cancer through a non-invasive blood-based test.
The partnership focuses on integrating AI and machine learning to enhance the accuracy and efficiency of the test, reducing diagnostic errors and enabling personalized medicine approaches. AOA will leverage Sonrai's cloud-based advanced analytics platform, pharma-grade data infrastructure, and bioinformatic expertise.
The multi-omic liquid biopsy test analyses various molecular biomarkers, such as circulating tumor DNA and cells, to provide precise insights into cancer presence and progression without the need for traditional tissue biopsies. The test leverages a combination of novel gangliosides, lipids, and proteins to diagnose ovarian cancer in women experiencing vague abdominal symptoms.
Dr Abigail McElhinny, Chief Scientific Officer of AOA Dx, stated that the partnership will allow AOA to integrate and manage their in-house development data, cross-reference it with public datasets, and analyse it seamlessly within one centralized environment. Sonrai will offer its bioinformatics expertise, enabling AOA to harness pre-built machine learning tools and run automated pipelines.
Prof. Darragh McArt, CEO and Founder of Sonrai Analytics, expressed delight about partnering with AOA Dx. He commented, "This partnership underscores our commitment to transforming the landscape of cancer diagnostics and treatment. By working together, we can bring a highly accurate, non-invasive test to market, which could significantly improve outcomes for women with ovarian cancer."
The partnership also aims to advance the development of the diagnostic test through a multi-omic biomarker validation strategy. Diagnosing women when symptoms first occur could transform the pathway for women, change outcomes, and offer significant savings to healthcare systems.
Other recent developments in the field include AbbVie receiving marketing authorisation from the MHRA, and Dxcover strengthening its leadership with world-class scientific advisors and board members. The AISight Dx platform, developed by PathAI, has also received clearance from the FDA.
As the partnership progresses, both Sonrai Analytics and AOA Dx look forward to bringing this groundbreaking diagnostic test to market, offering hope for early and accurate detection of ovarian cancer.
- The strategic partnership between Sonrai Analytics and AOA Dx, focusing on digital health and artificial intelligence, aims to accelerate the development of a multi-omic liquid biopsy test for ovarian cancer, thereby contributing to the science of medical-conditions and health-and-wellness.
- AOA will leverage Sonrai's technology and expertise, including their cloud-based advanced analytics platform and bioinformatic capabilities, in the hopes of improving early detection and personalized treatment of ovarian cancer through a non-invasive blood-based test.
- The test, which analyzes various molecular biomarkers such as circulating tumor DNA and cells, intends to offer precise insights into cancer presence and progression, replacing traditional tissue biopsies with a more futuristic approach.
- With this groundbreaking diagnostic test in the pipeline, the collaboration between Sonrai Analytics and AOA Dx signifies a significant leap forward in the realm of femtech news, potentially transforming the pathway for women with ovarian cancer while offering significant savings to healthcare systems.
